Skip to content
Screener

ArriVent BioPharma, Inc. AVBP Return on invested capital

Return on invested capital at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
19.2%+1.3pp
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-55.9%-7.1pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-67.9%-12.9pp
Nuvation Bio logo
Nuvation BioNUVB
-146.8%+87.5pp
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
-100.6%
Immunome logo
ImmunomeIMNM
-746.6%+212pp

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.44B+106%
Enterprise value$1.38B+135%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Calculated from ArriVent BioPharma, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-058650

FAQ

What is ArriVent BioPharma, Inc.'s return on invested capital?
ArriVent BioPharma, Inc. (AVBP) reported return on invested capital of -75.6% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about ArriVent BioPharma, Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude